What changed: Glioma & glioblastoma
Every dated change on the records linked to Glioma & glioblastoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 2
June 2025 · 1
2025 · 3
- 2025ApprovalDordaviproneDordaviprone approved in US
Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)
- 2025ApprovalVorasidenibVorasidenib approved in EU
Grade 2 IDH-mutant glioma ≥12 yrs; 17 Sep 2025
- 2025MilestoneDordaviproneDordaviprone approved for H3 K27M diffuse midline glioma
6 August 2025; first systemic therapy for the disease.
August 2024 · 1
2024 · 4
- 2024ApprovalTovorafenibTovorafenib approved in US
Relapsed/refractory BRAF-altered paediatric low-grade glioma (accelerated)
- 2024ApprovalVorasidenibVorasidenib approved in US
Grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, age ≥12
- 2024Trial resultGBM AGILEGBM AGILE reported
Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.
- 2024MilestoneVorasidenibVorasidenib approved
A milestone in how this cancer is treated.
March 2023 · 1
2023 · 3
2022 · 2
2021 · 1
2020 · 3
- 2020Trial resultCheckMate 143CheckMate 143 reported
OS 9.
- 2020Trial resultERGO2: ketogenic diet and fasting during re-irradiation of recurrent gliomaERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma reported
6-month PFS 20% vs 16%; median OS 11.
- 2020MilestoneCheckMate 143CheckMate 143: immunotherapy fails at recurrence
CheckMate 548 (2022) and CheckMate 498 (2023) follow in newly diagnosed disease; all three negative.
2017 · 4
- 2017Approval5-Aminolevulinic acid (oral, for glioma surgery)5-Aminolevulinic acid (oral, for glioma surgery) approved in US
Imaging agent for visualisation of malignant tissue during glioma surgery (suspected high-grade)
- 2017Trial resultCATNON (EORTC 26053-22054)CATNON (EORTC 26053-22054) reported
Adjuvant temozolomide: overall survival hazard ratio 0.
- 2017Trial resultCCTG CE.6 / EORTC 26062-22061 (Perry trial)CCTG CE.6 / EORTC 26062-22061 (Perry trial) reported
OS 9.
- 2017MilestoneCCTG CE.6 / EORTC 26062-22061 (Perry trial)Short-course radiotherapy plus temozolomide extends survival from age 65 (CCTG CE.6)
A milestone in how this cancer is treated.
2016 · 3
- 2016Trial resultACT IVACT IV reported
OS 20.
- 2016Trial resultEORTC 22033-26033EORTC 22033-26033 reported
Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.
- 2016MilestoneACT IVWHO 2016 integrates molecular markers; ACT IV vaccine fails
A milestone in how this cancer is treated.
October 2015 · 1
2015 · 2
2014 · 1
2013 · 2
April 2011 · 1
2011 · 1
2009 · 2
2008 · 1
2007 · 1
2006 · 1
2005 · 3
- 2005ApprovalTemozolomideTemozolomide approved in US
Newly diagnosed glioblastoma with radiotherapy
- 2005Trial resultEORTC 26981 / NCIC CE.3 (Stupp trial)EORTC 26981 / NCIC CE.3 (Stupp trial) reported
OS 14.
- 2005MilestoneGlioma & glioblastomaStupp regimen: temozolomide + RT
A milestone in how this cancer is treated.
1999 · 3
- 1999ApprovalTemozolomideTemozolomide approved in EU
Temodal; malignant glioma (recurrent 1999; newly diagnosed glioblastoma with radiotherapy 2005); 26 Jan 1999
- 1999ApprovalTemozolomideTemozolomide approved in US
Refractory anaplastic astrocytoma
- 1999MilestoneTemozolomideTemozolomide approved (anaplastic astrocytoma)
A milestone in how this cancer is treated.